NasdaqGS:INMD

Stock Analysis Report

Executive Summary

InMode Ltd. designs, develops, manufactures, and markets minimally-invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radio frequency technologies.

Snowflake

Fundamentals

Reasonable growth potential with adequate balance sheet.

Risks

  • InMode has significant price volatility in the past 3 months.

Similar Companies

Share Price & News

How has InMode's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

2.4%

NasdaqGS:INMD

1.5%

US Medical Equipment

0.8%

US Market


1 Year Return

n/a

NasdaqGS:INMD

9.7%

US Medical Equipment

1.9%

US Market

No trading data on INMD.

No trading data on INMD.


Share holder returns

INMDIndustryMarket
7 Day2.4%1.5%0.8%
30 Day34.0%0.7%3.4%
90 Dayn/a2.4%2.1%
1 Yearn/a10.6%9.7%4.2%1.9%
3 Yearn/a70.2%65.0%46.7%37.2%
5 Yearn/a136.0%109.1%62.3%44.5%

Price Volatility Vs. Market

How volatile is InMode's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is InMode undervalued based on future cash flows and its price relative to the stock market?

48%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

InMode's share price is below the future cash flow value, and at a moderate discount (> 20%).

InMode's share price is below the future cash flow value, and at a substantial discount (> 40%).


Price Based on Earnings

InMode is good value based on earnings compared to the US Medical Equipment industry average.

InMode is overvalued based on earnings compared to the United States of America market.


Price Based on Expected Growth

InMode is poor value based on expected growth next year.


Price Based on Value of Assets

InMode is overvalued based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is InMode expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

19.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

InMode's revenue is expected to grow by 18.7% yearly, however this is not considered high growth (20% yearly).

InMode's earnings are expected to grow by 19.6% yearly, however this is not considered high growth (20% yearly).

InMode's revenue growth is expected to exceed the United States of America market average.

InMode's earnings growth is expected to exceed the United States of America market average.

InMode's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

InMode is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).


Next Steps

Past Performance

How has InMode performed over the past 5 years?

70.2%

Last years earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Insufficient data to establish if InMode's year on year earnings growth rate was positive over the past 5 years.

Unable to compare InMode's 1-year earnings growth to the 5-year average due to insufficient past data.

InMode's earnings growth has exceeded the US Medical Equipment industry average in the past year (70.2% vs 28.9%).


Return on Equity

InMode made outstanding use of shareholders’ funds last year (Return on Equity greater than 40%).


Return on Assets

InMode used its assets more efficiently than the US Medical Equipment industry average last year based on Return on Assets.


Return on Capital Employed

Unable to establish if InMode improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to insufficient past data.


Next Steps

Financial Health

How is InMode's financial position?


Financial Position Analysis

InMode is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

InMode's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

InMode's level of debt (-0.8%) compared to net worth is satisfactory (less than 40%).

Unable to establish if InMode's debt level has increased without past 5-year debt data.

Operating cash flow is negative therefore debt is not well covered.

InMode has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet

Low level of unsold assets.

Debt is not covered by short term assets, assets are -154.6x debt.


Next Steps

Dividend

What is InMode's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate InMode's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate InMode's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as InMode has not reported any payouts.

Unable to verify if InMode's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as InMode has not reported any payouts.


Future Payout to Shareholders

No need to calculate the sustainability of InMode's dividends in 3 years as they are not expected to pay a notable one for United States of America.


Next Steps

Management

What is the CEO of InMode's salary, the management and board of directors tenure and is there insider trading?

7.2yrs

Average management tenure


CEO

Moshe Mizrahy (66yo)

11.7yrs

Tenure

0

Mr. Moshe Mizrahy is a Co-founder of Home Skinovations Ltd. and serves as its Chairman and Chief Executive Officer. Mr. Mizrahy is also a Co-founder of InsightLook Technologies Ltd., Nizanim Venture Capita ...


Management Age and Tenure

7.2yrs

Average Tenure

47yo

Average Age

The average tenure for the InMode management team is over 5 years, this suggests they are a seasoned and experienced team.


Board Age and Tenure

0.08yrs

Average Tenure

66yo

Average Age

The average tenure for the InMode board of directors is less than 3 years, this suggests a new board.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Moshe Mizrahy (66yo)

    Chairman & CEO

    • Tenure: 11.7yrs
  • Michael Kreindel (51yo)

    CTO & Director

    • Tenure: 0.08yrs
  • Yair Malca (41yo)

    Chief Financial Officer

    • Tenure: 2.7yrs
  • Shakil Lakhani (35yo)

    President of North America

    • Tenure: 2.7yrs
  • Spero Theodorou (47yo)

    Chief Medical Officer

    • Tenure: 0yrs

Board Members

  • Michael Anghel (80yo)

    Director

    • Tenure: 0.08yrs
  • Bruce Mann (84yo)

    Director

    • Tenure: 0.08yrs
  • Moshe Mizrahy (66yo)

    Chairman & CEO

    • Tenure: 11.7yrs
  • Hadar Ron (60yo)

    Director

    • Tenure: 0.08yrs
  • Michael Kreindel (51yo)

    CTO & Director

    • Tenure: 0.08yrs

Company Information

InMode Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: InMode Ltd.
  • Ticker: INMD
  • Exchange: NasdaqGS
  • Founded: 2008
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$878.634m
  • Shares outstanding: 31.97m
  • Website: https://www.inmodemd.com

Number of Employees


Location

  • InMode Ltd.
  • Tavor Building
  • Sha’ar Yokneam
  • Yokneam
  • 2069206
  • Israel

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
INMDNasdaqGS (Nasdaq Global Select)YesOrdinary SharesUSUSDAug 2019

Biography

InMode Ltd. designs, develops, manufactures, and markets minimally-invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radio freque ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/18 00:39
End of Day Share Price2019/09/17 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.